Literature DB >> 22133375

Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.

Deborah M Dickey1, Daniel L Dries, Kenneth B Margulies, Lincoln R Potter.   

Abstract

Cardiomyocytes release atrial natriuretic peptide (ANP) and B-type natriuretic peptide to stimulate processes that compensate for the failing heart by activating guanylyl cyclase (GC)-A. C-type natriuretic peptide is also elevated in the failing heart and inhibits cardiac remodeling by activating the homologous receptor, GC-B. We previously reported that GC-A is the most active membrane GC in normal mouse ventricles while GC-B is the most active membrane GC in failing ventricles due to increased GC-B and decreased GC-A activities. Here, we examined ANP and CNP-specific GC activity in membranes obtained from non-failing and failing human left ventricles and in membranes from matched cardiomyocyte-enriched pellet preparations. Similar to our findings in the murine study, we found that CNP-dependent GC activity was about half of the ANP-dependent GC activity in the non-failing ventricular and was increased in the failing ventricle. ANP and CNP increased GC activity 9- and 5-fold in non-failing ventricles, respectively. In contrast to the mouse study, in failing human ventricles, ANP-dependent activity was unchanged compared to non-failing values whereas CNP-dependent activity increased 35% (p=0.005). Compared with ventricular membranes, basal GC activity was reduced an order of magnitude in membranes derived from myocyte-enriched pellets from non-failing ventricles. ANP increased GC activity 2.4-fold but CNP only increased GC activity 1.3-fold. In contrast, neither ANP nor CNP increased GC activity in equivalent preparations from failing ventricles. We conclude that: 1) GC-B activity is increased in non-myocytes from failing human ventricles, possibly as a result of increased fibrosis, 2) human ventricular cardiomyocytes express low levels of GC-A and much lower levels or possibly no GC-B, and 3) GC-A in cardiomyocytes from failing human hearts is refractory to ANP stimulation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133375      PMCID: PMC4067042          DOI: 10.1016/j.yjmcc.2011.11.007

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  39 in total

Review 1.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

2.  Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes.

Authors:  S Del Ry; M Cabiati; F Vozzi; B Battolla; C Caselli; F Forini; C Segnani; T Prescimone; D Giannessi; L Mattii
Journal:  Peptides       Date:  2011-06-23       Impact factor: 3.750

3.  Prolonged atrial natriuretic peptide exposure stimulates guanylyl cyclase-a degradation.

Authors:  Darcy R Flora; Lincoln R Potter
Journal:  Endocrinology       Date:  2010-04-09       Impact factor: 4.736

4.  ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.

Authors:  Deborah M Dickey; Lincoln R Potter
Journal:  Clin Chem       Date:  2011-07-18       Impact factor: 8.327

Review 5.  Guanylyl cyclase structure, function and regulation.

Authors:  Lincoln R Potter
Journal:  Cell Signal       Date:  2011-09-10       Impact factor: 4.315

Review 6.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.

Authors:  Esther E Creemers; Yigal M Pinto
Journal:  Cardiovasc Res       Date:  2010-09-28       Impact factor: 10.787

7.  Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.

Authors:  Paula M Bryan; Xin Xu; Deborah M Dickey; Yingjie Chen; Lincoln R Potter
Journal:  Am J Physiol Renal Physiol       Date:  2007-01-30

Review 8.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Authors:  Lincoln R Potter; Andrea R Yoder; Darcy R Flora; Laura K Antos; Deborah M Dickey
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Novel bifunctional natriuretic peptides as potential therapeutics.

Authors:  Deborah M Dickey; John C Burnett; Lincoln R Potter
Journal:  J Biol Chem       Date:  2008-10-21       Impact factor: 5.157

10.  Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.

Authors:  Deborah M Dickey; Darcy R Flora; Paula M Bryan; Xin Xu; Yingjie Chen; Lincoln R Potter
Journal:  Endocrinology       Date:  2007-04-05       Impact factor: 4.736

View more
  10 in total

Review 1.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

2.  Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel.

Authors:  Ajit Vikram; Christopher M Lewarchik; Jin-Young Yoon; Asma Naqvi; Santosh Kumar; Gina M Morgan; Julia S Jacobs; Qiuxia Li; Young-Rae Kim; Modar Kassan; Jing Liu; Mohanad Gabani; Ajay Kumar; Haider Mehdi; Xiaodong Zhu; Xiaoqun Guan; William Kutschke; Xiaoming Zhang; Ryan L Boudreau; Shengchuan Dai; Daniel S Matasic; Saet-Byel Jung; Kenneth B Margulies; Vikas Kumar; Markus M Bachschmid; Barry London; Kaikobad Irani
Journal:  Nat Med       Date:  2017-02-13       Impact factor: 53.440

3.  A Glutamate-Substituted Mutant Mimics the Phosphorylated and Active Form of Guanylyl Cyclase-A.

Authors:  Neil M Otto; William G McDowell; Deborah M Dickey; Lincoln R Potter
Journal:  Mol Pharmacol       Date:  2017-04-17       Impact factor: 4.436

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

Review 5.  Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart.

Authors:  Akihiro Yasoda
Journal:  Biology (Basel)       Date:  2022-06-14

Review 6.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

Review 7.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

Review 8.  Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.

Authors:  Michael E J Preedy
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.727

9.  Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP.

Authors:  Hariharan Subramanian; Alexander Froese; Peter Jönsson; Hannes Schmidt; Julia Gorelik; Viacheslav O Nikolaev
Journal:  Nat Commun       Date:  2018-06-22       Impact factor: 14.919

Review 10.  Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.

Authors:  Alexandra Petraina; Cristian Nogales; Thomas Krahn; Hermann Mucke; Thomas F Lüscher; Rodolphe Fischmeister; David A Kass; John C Burnett; Adrian J Hobbs; Harald H H W Schmidt
Journal:  Cardiovasc Res       Date:  2022-07-20       Impact factor: 13.081

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.